



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:

Flannery et al.

Serial No: 09/463,844

Filed: February 1, 2000

For: ZGGBP1, Novel Peptides Related to  
Bipolar Affective Disorder Type 1,  
Sequences and Uses Thereof

Attorney Docket No. ASZD-P01-251

Art Unit: 1646

Examiner: O. Chernyshev

TECH CENTER 1600 2300

JUN 1 2 2002


RECEIVED

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, postage prepaid, in an envelope addressed to: Commissioner for Patents Washington, D.C. 20231 on the date indicated below:

May 22, 2002

Date of Signature  
and of Mail Deposit

  
Brent LaBarge

Commissioner of Patents  
Washington, D.C. 20231

**REPLY UNDER 37 CFR 1.111**

Sir:

This amendment is being filed in reply to the outstanding Office Action, mailed December 4, 2001, in connection with the above application. Please enter the following amendments:

In the specification:

◇◇ Please replace the third paragraph on page 1 with:

Family, twin and adoption studies have suggested the importance of genetic predisposition to bipolar affective disorder. On this basis, several groups have undertaken genetic linkage analysis in families with a high incidence of the disorder to find a causal gene. Many of the studies show conflicting data suggesting that a single gene is unlikely to be the cause. Rather, multiple interacting genetic traits may be involved. A recent study (Stine O.C. et